Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Hereditary Breast and Ovarian Cancer Syndrome Treatment Industry Expected To Reach By 2029, Starting From 2025 Levels?
The hereditary breast and ovarian cancer syndrome treatment market has experienced robust expansion in recent years. This market is projected to grow from $6.72 billion in 2024 to $7.07 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.2%. Historically, this expansion has been driven by factors such as increased awareness and screening, supportive government policies, patient advocacy and empowerment, and stronger collaboration in research efforts.
The hereditary breast and ovarian cancer syndrome treatment market is projected for substantial expansion in the coming years. This market is anticipated to reach a valuation of $8.98 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.2%. Factors driving this growth during the forecast period include the increasing influence of artificial intelligence, wider availability of genetic counseling, approval of targeted therapies by regulators, customized treatment approaches, and global research partnerships. Key trends foreseen for this period encompass gene editing technologies, progress in immunotherapy, technological innovations in oncology, the application of immunotherapy specifically for BRCA-related cancers, and an integrated multidisciplinary approach to patient care.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13209&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Industry?
An increase in genetic disorders is anticipated to fuel the expansion of the hereditary breast and ovarian cancer syndrome treatment market in the future. Newborn screening involves a physical examination conducted on all infants shortly post-birth to check for particular health conditions, enabling healthcare professionals to detect and address specific needs before a baby becomes ill. This screening can pinpoint infants with an elevated risk of developing breast and ovarian cancer, facilitating the early initiation of preventive strategies. As an illustration, in 2022, data from the Texas Department of State Health Services, a US-based state health agency, indicated that the overall number of specimens collected for newborn screening saw a rise of 4.3%, climbing from 729,347 in 2021 to 761,000 in 2022. Furthermore, approximately 394,000 infants underwent screening, with 1,130 infants identified as being affected by one of the NBS disorders during 2022. Consequently, the growing incidence of genetic disorders is serving as a catalyst for the expansion of the hereditary breast and ovarian cancer syndrome treatment market.
What Are The Leading Segments Analyzed In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
The hereditary breast and ovarian cancer syndrome treatmentmarket covered in this report is segmented –
1) By Treatment: Hormonal Therapy; Chemoprevention; Genetic Counselling; Medication; Other Treatments
2) By Diagnosis: Genetic Testing; Magnetic Resonance Imaging (MRI); Mammography; Other Diagnosis
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors
2) By Chemoprevention: Tamoxifen; Raloxifene
3) By Genetic Counselling: Risk Assessment; Family Planning Guidance
4) By Medication: Targeted Therapies; Immune Checkpoint Inhibitors
5) By Other Treatments: Preventive Surgery; Surveillance Strategies
What Trends Are Expected To Drive The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
Leading companies in the hereditary breast and ovarian cancer syndrome treatment market are implementing advanced treatment methods, such as extensive risk tests, to offer dependable services to clients. A comprehensive risk assessment test serves as a mechanism to determine an individual’s likelihood of developing a condition or showing signs of a disease. For example, in February 2023, Genetic Technologies Limited, a molecular diagnostics company based in Australia, unveiled a pioneering comprehensive risk assessment test, which is a form of treatment for breast and ovarian cancer. This test integrates gene mutation testing for breast and ovarian cancers, accounts for both hereditary and non-hereditary risk factors, and includes the GeneType risk score for both cancers. It employs a distinctive strategy that merges the identification of the 13 key actionable breast and ovarian cancer susceptibility genes with the GeneType test platform. This new testing platform is designed for women over 30 who, apart from rare genetic alterations, possess a higher risk of developing breast and ovarian cancer in the general population.
Which Key Market Players Are Investing In Expansion And Innovation Of Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care
Download The Full Report For Exclusive Market Findings:
Which Global Regions Are Influencing The Competitive Landscape Of The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13209&type=smp
Browse Through More Reports Similar to the Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market 2025, By The Business Research Company
Anorectal Disorders Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anorectal-disorders-treatment-global-market-report
Aspergillosis Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report
Histoplasmosis Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/histoplasmosis-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model